The FDA has approved atezolizumab (Tecentriq, and the subcutaneous formulation Tecentriq Hybreza) for adjuvant treatment of muscle-invasive bladder cancer — but not for everyone who has had their bladder removed. Eligibility is determined by a blood test. Only patients whose post-surgical blood shows detectable circulating tumor DNA (ctDNA) — a molecular sign that cancer cells are still shedding DNA fragments into the bloodstream, even when no tumor is visible on a scan — qualify for the drug. The agency has described it as the first approval to use ctDNA results to actively guide who receives therapy, rather than simply monitoring disease after the fact.
That is the real story here, more than the drug itself: a companion diagnostic, not a stage or grade on a pathology report, is what decides treatment eligibility.
What was approved
The approval covers atezolizumab as adjuvant (post-surgical) treatment in adults with muscle-invasive urothelial carcinoma who have undergone radical cystectomy (surgical bladder removal) and whose serial blood testing detects ctDNA, indicating molecular residual disease. Reporting on the approval places it in May 2026. Blood draws begin at least six weeks after surgery and continue on a defined schedule for up to a year; a positive ctDNA result at any point in that window is what triggers eligibility for the immunotherapy.
The companion diagnostic tied to the approval is Signatera CDx, a tumor-informed ctDNA assay from Natera that the FDA cleared alongside atezolizumab specifically to identify which patients “may benefit from treatment with these medicines,” per reporting on the approval. Tumor-informed means the test is built from a sample of the patient’s own resected tumor tissue, then used to design a personalized panel that screens blood draws for that same genetic signature — a materially more sensitive approach than a generic ctDNA panel, and part of why regulators were comfortable letting the result gate treatment rather than just inform it.
The trial: IMvigor011
The approval is built on data from IMvigor011, a randomized, placebo-controlled Phase 3 trial that enrolled patients who had already had their bladder removed and who tested ctDNA-positive after surgery — that is, the patients most likely to have micrometastatic disease that a CT or bone scan simply can’t see yet. Reported results describe a 36% reduction in the risk of disease recurrence or death (hazard ratio of roughly 0.64 for disease-free survival) and a 41% reduction in the risk of death (hazard ratio of roughly 0.59 for overall survival) for atezolizumab compared with placebo in this ctDNA-positive population.
The trial design matters as much as the numbers. Adjuvant immunotherapy trials in bladder cancer have historically enrolled everyone who fits a given stage after surgery, on the premise that some fraction of the group harbors residual disease that later recurs — but nobody could say in advance which patients that would be. IMvigor011 instead used ctDNA status as an enrollment filter, testing the hypothesis that a positive blood result identifies exactly the subgroup with enough residual disease burden to actually benefit from further systemic treatment, while sparing ctDNA-negative patients — who have a comparatively low recurrence risk — the toxicity and cost of a treatment they are unlikely to need.
Why this is a clinical-trial-design story, not just a drug story
Regulatory bodies and research funders have been pushing toward biomarker-defined trial populations for years — the FDA’s own Biomarker Qualification Program exists precisely to formalize how a biomarker earns the standing to be used this way in drug development. What’s notable about IMvigor011 is that the biomarker isn’t just a prognostic side-note reported alongside the primary endpoint; it’s the enrollment criterion and, downstream, the clinical eligibility gate. That has direct implications for how future adjuvant oncology trials get designed: a molecular test result, validated as an in vitro diagnostic and paired with the drug from the outset, increasingly functions as part of the intervention itself rather than as an ancillary lab measurement bolted onto a conventional trial. For anyone working in IVD-linked clinical trial design, this approval is a concrete, recent precedent for enrollment and treatment-eligibility strategies built around a companion diagnostic rather than staging alone.
It also reframes what “surveillance” after cancer surgery can mean. Serial ctDNA testing has been used for a few years now mainly to flag recurrence earlier than imaging can — useful, but not, on its own, something that changed treatment. Tying a specific therapy to a specific test result turns that same blood draw into an active decision point rather than a watch-and-wait tool.
What it does not mean
This is an adjuvant treatment approval for a defined, ctDNA-positive subgroup of bladder cancer patients who have already had surgery — not a cure, not a treatment for metastatic disease, and not a blanket approval for everyone diagnosed with muscle-invasive bladder cancer. Patients who test ctDNA-negative after surgery are not part of the approved population under this decision. As with any adjuvant immunotherapy, the reported benefit is a reduction in the risk of recurrence or death relative to placebo in a defined trial population — not a guarantee for any individual patient.
Source
Reporting drawn from WebMD’s drug-update coverage of the FDA action: “Tecentriq and Tecentriq Hybreza: FDA Approves First ctDNA-Guided Adjuvant Immunotherapies”, corroborated by independent trade coverage of the same approval and the associated Signatera CDx companion-diagnostic clearance. CASRAI was unable to retrieve the original FDA.gov approval notice directly at time of writing; readers should check FDA’s Hematology/Oncology approvals listing for the primary regulatory record.
